Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Meropenem

A broad-spectrum carbapenem antibiotic, patented in 1983 and approved in the United States in 1996: it is given intravenously for serious infections such as pneumonia, meningitis and abdominal infections. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.

Did you know?Carbapenems descend from thienamycin, produced by the bacterium Streptomyces cattleya; unlike imipenem, meropenem resists the kidney enzyme dehydropeptidase-I and does not need to be paired with cilastatin.

MeropenemGo to the active ingredient →
MeropenemActive ingredientMeropenemCat. No. P-M062-001CAS 96036-03-2
Meropenem-d6Isotopically labelledMeropenem-d6Cat. No. P-M062-009CAS 1133424-00-6

EDQM standards 1

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.